Related Experiment Video
Updated: Jun 3, 2025
Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence
Published on: September 22, 2023
Efficacy and Safety of Specific Immunotherapy Combined with Biologics in Allergic Rhinitis and Asthma: A Systematic
Dayu Guan1, Yijun Liu2, Yue Gu2
1Department of Otorhinolaryngology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China, 1219729774@qq.com.
Introduction:
Allergic diseases are common clinical diseases. Although allergen-specific immunotherapy (AIT) and biologics have been widely recognized, the clinical efficacy, safety, advantages, and disadvantages of the combined application have not yet been sufficiently recognized. We aimed to investigate the efficacy and safety of AIT combined with biologics in patients with allergic rhinitis and asthma.
Methods:
PubMed, Embase, the Cochrane Library, and Web of Science were systematically searched to identify studies investigating AIT combined with biologics for treating allergic rhinitis and asthma. The relevant outcome indicators, including incidences of emergency drug use, severe nasal symptoms, severe adverse effects (AEs), local reactions at the site of administration, headache, and general AEs, were collected and extracted. Routine and network meta-analyses were conducted using RevMan-5.4 and STATA-MP-14 to assess efficacy and safety.
Results:
Eight RCTs and a retrospective study involving 1,494 patients aged 5-65 years with allergic rhinitis and asthma were included in this review. (1) Routine meta-analysis revealed that AIT combined with biologics was significantly better than control treatment (placebo, AIT, or biologics) in terms of the incidence of emergency drug use, severe nasal symptoms, and severe AEs (p = 0.0002; p = 0.01; p = 0.02). However, the differences in the incidence of local reactions at the site of administration, headache, and general AEs were not significant. (2) In the network meta-analysis, compared with AIT or placebo alone, AIT combined with biologics observably reduced the incidence of emergency drug use and severe nasal symptoms (OR = 0.32, 95% CI 0.14-0.73; OR = 0.41, 95% CI: 0.26-0.63). Furthermore, AIT combined with biologics yielded an evidently lower incidence of serious adverse reactions than AIT alone (OR = 0.42, 95% CI: 0.23-0.74).
Conclusion:
The combined application of AIT and biologics has promising prospects in the clinical treatment of allergic rhinitis and asthma due to the improvement of both clinical efficacy and safety (trial registration: Systemic Review Registration; PROSPERO #CRD42024496277).
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
02:06Allergic Reactions
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...